J A Cohen

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Ann Neurol 69:759-77. 2011
  2. ncbi Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    Jeffrey A Cohen
    Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 362:402-15. 2010
  3. ncbi Emerging therapies for relapsing multiple sclerosis
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Arch Neurol 66:821-8. 2009
  4. ncbi Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
    J A Cohen
    Mellen Center U 10, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurology 72:535-41. 2009
  5. ncbi The future of multiple sclerosis treatment
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA
    J Neurol Sci 277:S55-61. 2009
  6. ncbi Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
    J A Cohen
    Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 14:370-82. 2008
  7. ncbi Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS
    J A Cohen
    Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Neurology 68:939-44. 2007
  8. ncbi Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial
    J A Cohen
    The Mellen Center U10, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Arch Neurol 58:961-7. 2001
  9. ncbi Benefit of interferon beta-1a on MSFC progression in secondary progressive MS
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:679-87. 2002
  10. ncbi Assessing disability progression with the Multiple Sclerosis Functional Composite
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44106, USA
    Mult Scler 15:984-97. 2009

Detail Information

Publications21

  1. ncbi Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Ann Neurol 69:759-77. 2011
    ..5 to 10x the approved 0.5 mg dose. Fingolimod's unique mechanism of action distinguishes it from all other currently approved MS therapies...
  2. ncbi Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
    Jeffrey A Cohen
    Mellen Center, Cleveland Clinic, Cleveland, OH 44195, USA
    N Engl J Med 362:402-15. 2010
    ..Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on imaging in a phase 2 study involving patients with multiple sclerosis...
  3. ncbi Emerging therapies for relapsing multiple sclerosis
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Arch Neurol 66:821-8. 2009
    ..A sizable number of new agents are under investigation currently. This article reviews emerging agents that have shown promise in phase 2 trials...
  4. ncbi Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS
    J A Cohen
    Mellen Center U 10, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Neurology 72:535-41. 2009
    ..v. methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNbeta-1a monotherapy...
  5. ncbi The future of multiple sclerosis treatment
    Jeffrey A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH, USA
    J Neurol Sci 277:S55-61. 2009
    ..The place that these therapies will come to occupy in future years will depend on their relative benefits and risks...
  6. ncbi Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
    J A Cohen
    Mellen Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Mult Scler 14:370-82. 2008
    ....
  7. ncbi Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS
    J A Cohen
    Mellen Center for MS Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Neurology 68:939-44. 2007
    ..To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing-remitting multiple sclerosis...
  8. ncbi Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial
    J A Cohen
    The Mellen Center U10, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    Arch Neurol 58:961-7. 2001
    ..The MSFC is the primary outcome measure in the ongoing multinational phase 3 trial of interferon beta-1a (Avonex) in patients with secondary progressive MS...
  9. ncbi Benefit of interferon beta-1a on MSFC progression in secondary progressive MS
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:679-87. 2002
    ..Studies of other IFNbeta preparations in secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNbeta-1a slowed disease progression in SP-MS...
  10. ncbi Assessing disability progression with the Multiple Sclerosis Functional Composite
    R A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, OH 44106, USA
    Mult Scler 15:984-97. 2009
    ..However, the clinical meaning of an MSFC Z-score change is not obvious. This study instead used MSFC component data to define a patient-specific disease progression event...
  11. ncbi Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    J Neuroimmunol 98:29-36. 1999
    ..Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary...
  12. ncbi A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta
    D R Smith
    Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
    Mult Scler 11:573-82. 2005
    ..75; P =0.011). CY/MP treatment was well tolerated. CONCLUSION: Combination therapy with CY/MP and IFNbeta-Ia decreased the number of Gd+ lesions and slowed clinical activity in patients with previously active disease on IFNbeta alone...
  13. ncbi Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study
    D M Miller
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Mult Scler 12:180-6. 2006
    ..The IMPACT data permit a detailed assessment of the relation between clinical and self-reported measures...
  14. ncbi Multiple sclerosis: the importance of early recognition and treatment
    R J Fox
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 68:157-71. 2001
    ..Several lines of evidence demonstrate that tissue damage occurs very early in the disease, and much of this damage is clinically silent...
  15. ncbi Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  16. ncbi Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite
    L J Balcer
    Division of Neuro ophthalmology, Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia 19104, USA
    Neurology 61:1367-73. 2003
    ..Visual dysfunction is one of the most common causes of disability in multiple sclerosis (MS). The Multiple Sclerosis Functional Composite (MSFC), a new clinical trial outcome measure, does not currently include a test of visual function...
  17. ncbi Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis
    B A C Cree
    Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, 350 Parnassus Ave, Suite 908, San Francisco, CA 94117, USA
    Neurology 63:2039-45. 2004
    ..African American (AA) individuals are thought to develop multiple sclerosis (MS) less frequently than Caucasian American (CA) individuals...
  18. ncbi Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study
    A D Goodman
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA rmc rochester edu
    Mult Scler 13:357-68. 2007
    ..To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg twice daily...
  19. ncbi Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis
    M L Baier
    Center for Research Methodology and Biometrics, Cooper Institute, 14023 Denver West Parkway, 100, Golden, CO 80401, USA
    Neurology 64:992-5. 2005
    ..To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis Functional Composite (MSFC)...
  20. ncbi Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment
    C H Polman
    Department of Neurology, Free University Medical Center in Amsterdam, PO Box 4075, 1007 MB Amsterdam, The Netherlands
    Neurology 70:1134-40. 2008
    ..Guidance is also provided on the ethics of alternative trial designs and the balance between study subject burden and risk, scientific rationale and interpretability of trial outcomes...
  21. ncbi Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects
    H L Weiner
    Multiple Sclerosis Center, Brigham and Women s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston 02115, USA
    Mult Scler 8:142-54. 2002
    ..Cyclophosphamide is currently used in patients whose disease is not controlled by beta-interferon or glatiramer acetate and those with rapidly worsening MS...